Crown J
St. Vincent's Hospital, Dublin, Ireland.
Ann Oncol. 1995;6 Suppl 1:11-4; discussion 14-5. doi: 10.1093/annonc/6.suppl_1.s11.
The use of high-dose chemotherapy (HDC) in the range requiring autologous haematopoietic stem cell support can produce very high rates of response in patients with a variety of solid tumours but it remains controversial. The solid tumour in which HDC has been most extensively studied is breast cancer, and this disease is used as a model for the current discussion. Comparisons are made with ovarian, testicular and small-cell lung cancers and random assignment trials are suggested to demonstrate and to quantitate any survival advantages associated with therapy. Further development work is indicated.
在需要自体造血干细胞支持的剂量范围内使用大剂量化疗（HDC），可使多种实体瘤患者产生很高的缓解率，但仍存在争议。对HDC进行了最广泛研究的实体瘤是乳腺癌，本病用作当前讨论的模型。文中将其与卵巢癌、睾丸癌和小细胞肺癌进行了比较，并建议开展随机分配试验，以证明并量化与治疗相关的任何生存优势。指明了进一步的研发工作。
